Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab for ROP in Chinese Preterm Infants (Real‑World, Phase IV)
CTR20222720Phase 4Completed
- Sponsor
- Novartis
- Start
- Oct 2022
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of ranibizumab in retinopathy of prematurity (ROP), sponsored by Novartis. Started Oct 2022; status: completed.
02
Drugs
ranibizumab
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on CTR20222720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222720.